GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » Shares Outstanding (EOP)

Redx Pharma (LSE:REDX) Shares Outstanding (EOP) : 334.91 Mil (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Redx Pharma's shares outstanding for the quarter that ended in Sep. 2023 was 334.91 Mil.

Redx Pharma's quarterly shares outstanding stayed the same from Mar. 2023 (334.91 Mil) to Sep. 2023 (334.91 Mil).

Redx Pharma's annual shares outstanding stayed the same from Sep. 2022 (334.91 Mil) to Sep. 2023 (334.91 Mil).


Redx Pharma Shares Outstanding (EOP) Historical Data

The historical data trend for Redx Pharma's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma Shares Outstanding (EOP) Chart

Redx Pharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 126.54 195.35 275.28 334.91 334.91

Redx Pharma Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 275.28 275.28 334.91 334.91 334.91

Competitive Comparison of Redx Pharma's Shares Outstanding (EOP)

For the Biotechnology subindustry, Redx Pharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redx Pharma's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Redx Pharma's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Redx Pharma's Shares Outstanding (EOP) falls into.



Redx Pharma Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Redx Pharma  (LSE:REDX) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Redx Pharma Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Redx Pharma's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Redx Pharma (LSE:REDX) Business Description

Traded in Other Exchanges
N/A
Address
Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG
Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines